Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00082
|
|||||
Drug Name |
Methotrexate
|
|||||
Synonyms |
(S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; A-Methopterin; A-Methpterin; Abitrexate; Amethopterin; Amethopterin L-; Amethopterine; Antifolan; Folex-Pfs; Hdmtx; L-Amethopterin; MTX; Maxtrex; Metatrexan; Methotextrate; Methotrexat; Methotrexat-Ebewe; Methotrexate, L-; Methotrexatum; Methylaminopterin; Methylaminopterinum; Metotressato [DCIT]; Metotrexato; Mexate; Mexate-Aq; N-Bismethylpteroylglutamic acid; Rasuvo; Rheumatrex; [3H]methotrexate; methotrexate
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Leukemia [ICD11: 2A60-2B33] | Approved | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C20H22N8O5
|
|||||
Canonical SMILES |
CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
|
|||||
InChI |
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
|
|||||
InChIKey |
FBOZXECLQNJBKD-ZDUSSCGKSA-N
|
|||||
CAS Number |
CAS 59-05-2
|
|||||
Pharmaceutical Properties | Molecular Weight | 454.4 | Topological Polar Surface Area | 211 | ||
Heavy Atom Count | 33 | Rotatable Bond Count | 9 | |||
Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 12 | |||
XLogP |
-1.8
|
|||||
PubChem CID | ||||||
ChEBI ID |
ChEBI:44185
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
FLOT1 | Transporter Info | Folate transporter 1 | Substrate | [3] | ||
MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [4] | ||
MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [5] | ||
MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [6] | ||
MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [7] | ||
MRP5 | Transporter Info | Multidrug resistance-associated protein 5 | Substrate | [8] | ||
MRP8 | Transporter Info | Multidrug resistance-associated protein 8 | Substrate | [9] | ||
OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [10] | ||
OAT2 | Transporter Info | Organic anion transporter 2 | Substrate | [11] | ||
OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [12] | ||
OAT4 | Transporter Info | Organic anion transporter 4 | Substrate | [13] | ||
OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [14] | ||
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [15] | ||
OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [16] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [17] | ||
PCFT | Transporter Info | Proton-coupled folate transporter | Substrate | [18] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | BCRP | Transporter Info | Km = 681 microM | Breast carcinoma cell line (MCF7)-BCRP | [2] | |
BCRP | Transporter Info | Km = 1340 microM | Human embryonic kidney cells (HEK293)-BCRP | [19] | ||
BCRP | Transporter Info | Km = 1410 microM | Human embryonic kidney cells (HEK293)-BCRP | [20] | ||
MRP1 | Transporter Info | Km = 930 microM | Breast carcinoma cell line (MCF7)-MRP1 | [6] | ||
MRP1 | Transporter Info | Km = 2150 microM | Human embryonic kidney cells (HEK293)-MRP1 | [4] | ||
MRP1 | Transporter Info | Km = 2150 microM | NIH3T3-MRP1 | [4] | ||
MRP2 | Transporter Info | Km = 480 microM | Human embryonic kidney cells (HEK293)-MRP2 | [7] | ||
MRP3 | Transporter Info | Km = 910 microM | Breast carcinoma cell line (MCF7)-MRP3 | [6] | ||
MRP3 | Transporter Info | Km = 620 microM | Human embryonic kidney cells (HEK293)-MRP3 | [4] | ||
MRP3 | Transporter Info | Km = 776 microM | Human embryonic kidney cells (HEK293)-MRP3 | [21] | ||
MRP4 | Transporter Info | Km = 220 microM | Human embryonic kidney cells (HEK293)-MRP4 | [7] | ||
MRP4 | Transporter Info | Km = 220 microM | Spodoptera frugiperda (Sf9) cells-MRP4 | [22] | ||
MRP4 | Transporter Info | Km = 1300 microM | Spodoptera frugiperda (Sf9) cells-MRP4 | [23] | ||
MRP5 | Transporter Info | Km = 1174 microM | Human embryonic kidney cells (HEK293)-MRP5 | [24] | ||
MRP5 | Transporter Info | Km = 1200 microM | Human embryonic kidney cells (HEK293)-MRP5 | [8] | ||
MRP8 | Transporter Info | Km = 957 microM | LLC-PK1 cells-MRP8 | [25] | ||
OAT1 | Transporter Info | Km = 724 microM | Oocytes-OAT1 | [12] | ||
OAT1 | Transporter Info | Km = 554 microM | Proximal tubule (S2) cells-OAT1 | [13] | ||
OAT3 | Transporter Info | Km = 10.9 microM | Oocytes-OAT3 | [26] | ||
OAT3 | Transporter Info | Km = 17.2 microM | Oocytes-OAT3 | [12] | ||
OAT3 | Transporter Info | Km = 21.1 microM | Oocytes-OAT3 | [13] | ||
OAT3 | Transporter Info | Km = 21.1 microM | Proximal tubule (S2) cells-OAT3 | [13] | ||
OAT4 | Transporter Info | Km = 17.8 microM | Proximal tubule (S2) cells-OAT4 | [13] | ||
OATP1A2 | Transporter Info | Km = 457 microM | Oocytes-OATP1A2 | [14] | ||
OATP1B3 | Transporter Info | Km = 39.4 microM | Madin-Darby canine kidney (MDCK) cells-OATP1B3 | [16] | ||
OATP1B3 | Transporter Info | Km = 24.7 microM | Oocytes-OATP1B3 | [16] | ||
PCFT | Transporter Info | Km = 4.2 microM | Model organism in vivo (rat) | [18] | ||
References | ||||||
1 | Methotrexate was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43. | |||||
3 | Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204. | |||||
4 | Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. | |||||
5 | Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61. | |||||
6 | Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37. | |||||
7 | Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35. | |||||
8 | The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30. | |||||
9 | ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 2010 Nov;101(11):2404-10. | |||||
10 | Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9. | |||||
11 | Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158. | |||||
12 | Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74. | |||||
13 | Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. | |||||
14 | Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9. | |||||
15 | Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69. | |||||
16 | LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99. | |||||
17 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
18 | Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol. 2009 Jul;61(7):911-8. | |||||
19 | Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54. | |||||
20 | Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. | |||||
21 | Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000 Sep 1;60(17):4779-84. | |||||
22 | Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. | |||||
23 | The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002 Mar;13(3):595-603. | |||||
24 | Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci. 2006 Apr;27(5):524-32. | |||||
25 | Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. | |||||
26 | Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.